《抗微生物药物与化疗》（Antimicrobial Agents and Chemotherapy，简称 AAC）是由美国微生物学会（American Society for Microbiology，ASM）出版的同行评审学术期刊。Antimicrobial Agents and Chemotherapy (AAC) is a peer-reviewed academic journal published by the American Society for Microbiology (ASM).
该期刊主要发表有关抗微生物药物、抗寄生虫药物及癌症化疗领域的跨学科研究成果。The journal primarily publishes interdisciplinary research concerning antimicrobial, antiparasitic, and cancer chemotherapy agents.
该期刊涵盖与抗微生物制剂的设计、作用机制及临床应用相关的广泛主题。The journal encompasses a broad spectrum of topics related to the design, mechanism of action, and clinical application of antimicrobial agents.
核心研究领域包括新型抗生素与抗病毒化合物的发现与合成。Core research areas include the discovery and synthesis of novel antibiotic and antiviral compounds.
它发表探讨细菌耐药机制、遗传学决定簇及耐药表型的基础与转化研究。It features fundamental and translational studies exploring mechanisms of bacterial resistance, genetic determinants, and resistant phenotypes.
药理学也是其重点领域，包括临床前体外模型、体内动物模型研究以及药代动力学与药效学（PK/PD）建模。Pharmacology represents another major focus, including preclinical in vitro models, in vivo animal studies, and pharmacokinetic and pharmacodynamic (PK/PD) modeling.
此外，该刊还接收有关抗感染疗法的临床试验、联合用药策略及创新药物递送系统的研究论文。Additionally, the journal accepts manuscripts addressing clinical trials of anti-infective therapies, combination regimens, and innovative drug delivery systems.
美国微生物学会于1972年正式创办了《抗微生物药物与化疗》期刊。The American Society for Microbiology officially established Antimicrobial Agents and Chemotherapy in 1972.
创刊初期，格拉迪斯·霍比（Gladys L. Hobby）担任第一任主编，为该刊确立了严谨的审稿标准。At its inception, Gladys L. Hobby served as the founding editor-in-chief, establishing rigorous editorial standards for the publication.
在期刊独立发行之前，ASM 曾以年度会议论文集的形式出版同名系列文献。Prior to the journal's launch as a standalone periodical, ASM had published a series of annual conference proceedings under the same title.
随着抗微生物耐药性（AMR）日益成为全球公共卫生关注的焦点，该刊逐渐发展成为抗感染药理学领域的核心出版物之一。As antimicrobial resistance (AMR) emerged as a pressing global public health priority, the journal developed into one of the flagship publications in anti-infective pharmacology.
近年来，该期刊逐步转向纯数字化出版模式，以加快审稿周期并支持科研数据的开放共享。In recent years, the journal transitioned toward an online-only publishing format to accelerate review turnaround times and support open research data sharing.
期刊的编辑架构由一名主编以及多名资深编辑和编委会成员共同组成。The editorial structure consists of an editor-in-chief supported by multiple senior editors and an editorial board.
塞萨尔·阿里亚斯（Cesar A. Arias）教授曾长期担任该刊主编，重点推动了临床分子耐药机制与转化医学研究的报道。Dr. Cesar A. Arias has served as the editor-in-chief, significantly expanding the journal's coverage of molecular resistance mechanisms and translational medicine.
除主编外，各编辑分别负责专门的细分领域，包括实验性化疗、抗结核研究、真菌药理学以及宿主防御反应。Alongside the editor-in-chief, specialized editors oversee dedicated sections including experimental chemotherapy, mycobacterial research, fungal pharmacology, and host-defense interactions.
编委会由来自全球学术界、临床机构及药物研发机构的数百名资深学者组成，全面负责稿件的同行评议流程。The editorial board is composed of hundreds of established scholars from global academia, clinical institutions, and drug discovery sectors who manage the peer-review process.